KR20020092958A - 항종양 활성을 가진 옥시- 및 아미노-치환된테트라하이드로푸릴 유도체 - Google Patents

항종양 활성을 가진 옥시- 및 아미노-치환된테트라하이드로푸릴 유도체 Download PDF

Info

Publication number
KR20020092958A
KR20020092958A KR1020027010697A KR20027010697A KR20020092958A KR 20020092958 A KR20020092958 A KR 20020092958A KR 1020027010697 A KR1020027010697 A KR 1020027010697A KR 20027010697 A KR20027010697 A KR 20027010697A KR 20020092958 A KR20020092958 A KR 20020092958A
Authority
KR
South Korea
Prior art keywords
substituted
unsubstituted
independently
alkyl
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020027010697A
Other languages
English (en)
Korean (ko)
Inventor
히가타츠오
타나카주우니치
가르시아갈바로스돌로레스
Original Assignee
파르마 마르.에스.에이.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0003629A external-priority patent/GB0003629D0/en
Priority claimed from GB0021774A external-priority patent/GB0021774D0/en
Application filed by 파르마 마르.에스.에이. filed Critical 파르마 마르.에스.에이.
Publication of KR20020092958A publication Critical patent/KR20020092958A/ko
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D307/18—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/20—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D307/18—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/22—Nitrogen atoms not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Furan Compounds (AREA)
KR1020027010697A 2000-02-16 2001-02-16 항종양 활성을 가진 옥시- 및 아미노-치환된테트라하이드로푸릴 유도체 Ceased KR20020092958A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0003629A GB0003629D0 (en) 2000-02-16 2000-02-16 Antitumour agent
GB0003629.3 2000-02-16
GB0021774.5 2000-09-05
GB0021774A GB0021774D0 (en) 2000-09-05 2000-09-05 Anti-tumour compound
PCT/GB2001/000655 WO2001060810A1 (en) 2000-02-16 2001-02-16 Oxy-and amino-substituted tetrahydrofuryl derivatives with antitumour activity

Publications (1)

Publication Number Publication Date
KR20020092958A true KR20020092958A (ko) 2002-12-12

Family

ID=26243662

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020027010697A Ceased KR20020092958A (ko) 2000-02-16 2001-02-16 항종양 활성을 가진 옥시- 및 아미노-치환된테트라하이드로푸릴 유도체

Country Status (17)

Country Link
US (1) US6864283B2 (cg-RX-API-DMAC7.html)
EP (1) EP1255746B1 (cg-RX-API-DMAC7.html)
JP (1) JP2003523338A (cg-RX-API-DMAC7.html)
KR (1) KR20020092958A (cg-RX-API-DMAC7.html)
CN (1) CN1318409C (cg-RX-API-DMAC7.html)
AT (1) ATE316524T1 (cg-RX-API-DMAC7.html)
AU (2) AU2001233873B2 (cg-RX-API-DMAC7.html)
BR (1) BR0108448A (cg-RX-API-DMAC7.html)
CA (1) CA2400612C (cg-RX-API-DMAC7.html)
CZ (1) CZ20022791A3 (cg-RX-API-DMAC7.html)
DE (1) DE60116855T2 (cg-RX-API-DMAC7.html)
ES (1) ES2256199T3 (cg-RX-API-DMAC7.html)
IL (1) IL151241A (cg-RX-API-DMAC7.html)
MX (1) MXPA02007995A (cg-RX-API-DMAC7.html)
PL (1) PL357193A1 (cg-RX-API-DMAC7.html)
RU (1) RU2002124591A (cg-RX-API-DMAC7.html)
WO (1) WO2001060810A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001233873B2 (en) 2000-02-16 2006-03-02 Pharma Mar, S.A. Oxy-and amino-substituted tetrahydrofuryl derivatives with antitumour activity
CN102229585A (zh) * 2011-04-26 2011-11-02 中国人民解放军第二军医大学 具有抗肿瘤活性的γ-丁内酯聚酮类化合物
LT3615544T (lt) 2017-04-27 2023-05-10 Pharma Mar S.A. Priešnavikiniai junginiai

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5583160A (en) * 1989-02-03 1996-12-10 The Biomembrane Institute Methylsphingosine used to treat apoptosis
CA2007507C (en) * 1989-02-03 1998-05-19 Yasuyuki Igarashi Sphingosine and n-methyl-sphingosine as inhibitor of cell growth
US6107520A (en) * 1997-04-15 2000-08-22 The Board Of Trustees Of The University Of Illinois Spisulosine compounds
AU2001233873B2 (en) 2000-02-16 2006-03-02 Pharma Mar, S.A. Oxy-and amino-substituted tetrahydrofuryl derivatives with antitumour activity

Also Published As

Publication number Publication date
EP1255746A1 (en) 2002-11-13
WO2001060810A1 (en) 2001-08-23
US20030092738A1 (en) 2003-05-15
ES2256199T3 (es) 2006-07-16
AU3387301A (en) 2001-08-27
AU2001233873B2 (en) 2006-03-02
RU2002124591A (ru) 2004-01-10
DE60116855D1 (de) 2006-04-13
CA2400612A1 (en) 2001-08-23
CA2400612C (en) 2010-05-11
CN1423642A (zh) 2003-06-11
US6864283B2 (en) 2005-03-08
DE60116855T2 (de) 2006-09-14
JP2003523338A (ja) 2003-08-05
BR0108448A (pt) 2003-04-01
MXPA02007995A (es) 2003-05-23
CZ20022791A3 (cs) 2003-02-12
WO2001060810B1 (en) 2001-11-29
EP1255746B1 (en) 2006-01-25
PL357193A1 (en) 2004-07-26
CN1318409C (zh) 2007-05-30
ATE316524T1 (de) 2006-02-15
IL151241A (en) 2006-10-31

Similar Documents

Publication Publication Date Title
AU2020352337B2 (en) EP300/CBP inhibitor
CN1148391A (zh) 通过与聚吡咯甲酰氨基萘衍生物连接提高生物活性化合物的生物药效性
CN101711154A (zh) 氨基甲酸酯化合物
Lee et al. Investigation of amino acid conjugates of (S)-1-[1-(4-aminobenzoyl)-2, 3-dihydro-1H-indol-6-sulfonyl]-4-phenyl-imidazolidin-2-one (DW2282) as water soluble anticancer prodrugs
CS208798B2 (en) Method of making the new derivatives of the n-substituted aziridin-2-carboxyl acid
US20250248990A1 (en) Quinolines that modulate serca and their use for treating disease
CN113698401A (zh) β-榄香烯大环衍生物及其制备方法和应用
CN1712399B (zh) 紫杉醇和免疫增强剂胞壁酰二肽共轭物的制备及用途
EP1255746B1 (en) Oxy- and amino-substituted tetrahydrofuryl derivatives with antimour activity
AU2001233873A1 (en) Oxy-and amino-substituted tetrahydrofuryl derivatives with antitumour activity
EP0320988A2 (en) Epipodophyllotoxin glucoside 4'-acyl derivative
CN101463029B (zh) 紫杉烷衍生物及其制法和用途
JP2002526540A (ja) 細胞毒性アルカロイド類(ハリツリン)
JP2000502351A (ja) 医薬化合物
TW200301114A (en) Crystals of taxane derivative and process for the production thereof
CN106317175B (zh) 组蛋白去乙酰化酶抑制剂及其制备方法和应用
CN104119295B (zh) 吩噻嗪类一氧化氮供体、其制备方法和用途
CN104098594A (zh) 生物素-鬼臼毒素酯化衍生物及其药物组合物和其制备方法与应用
CN102153548B (zh) 一种含有噻唑(嗪)烷酮环的类核苷衍生物及其制备方法和其在药物制剂中的应用
JPH11513361A (ja) 環状駆虫性阻害剤
EP1286990B1 (en) Stolonoxides
WO2009111502A2 (en) Anti-cancer compounds, synthesis thereof, and methods of using same
JPH04198185A (ja) イソチアゾロ〔5,4―b〕ピリジン誘導体
AU2001254938A1 (en) Stolonoxides
JPH0517419A (ja) 新規化合物および該化合物を有効成分とする抗腫瘍剤

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20020816

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20060216

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20061208

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20070607

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20061208

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I